Merck in Late-Stage Talks to Acquire Prometheus Biosciences Inc for Immune Disease Treatments
Merck & Co. is in the final stages of negotiations to acquire Prometheus Biosciences, Inc., a bioscience company that focuses on innovative therapies for immune and inflammatory disorders. According to sources familiar with the matter, the deal is expected to be completed soon, marking another major pharmaceutical acquisition in the biotech industry. This move is … Read more